Status:
UNKNOWN
Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer
Lead Sponsor:
Show Chwan Memorial Hospital
Conditions:
Arthralgia
Eligibility:
FEMALE
20-90 years
Phase:
NA
Brief Summary
Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause, but side effects, such as joint pain, would affect their qualities of life. Chinese herbs or ac...
Detailed Description
Reduce estrogen exposure can lower the risk of breast cancer recurrence. Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause for years. It can incre...
Eligibility Criteria
Inclusion
- Women with diagnosis of early breast cancer (stages I-III), expressing hormone receptor-positive (ER+, PR+, or both) and took third generation aromatase inhibitors (AIs).
- Post- or pre-menopausal with the use of a gonadotropin-releasing hormone agonist.
- Taking AIs for more than 30 days before registration and planned to continue treatment for over 1 year.
- Have already been recovered from the surgery or chemotherapy.
- Have a ECOG performance status score of 0 to 1.
- Joint pain which has developed or worsened since starting AIs therapy. The worst pain item score of Brief Pain Inventory-Short Form (BPI-SF) is at least 3 and above.
- Have a Eastern Cooperative Oncology Group (ECOG) grading scale for chemotherapy-induced peripheral neuropathy score of 1 to 2.
- The patient could cooperate the intervention and sign the informed consent.
Exclusion
- Had received acupuncture treatment for joint pain would be excluded, but patients with acupuncture treatment for less than 2 times due to other reasons could be included.
- Had a history of fractures or underwent surgery on the knee or hand joints in the past six months.
- Had severe bleeding disorders. The platelet counts are below 50,000 per μl.
- Cognitive disorders (included dementia).
- Lymphedema after breast cancer surgery.
Key Trial Info
Start Date :
May 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 3 2023
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05264649
Start Date
May 5 2022
End Date
March 3 2023
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ShowChwanMH
Changhua, Taiwan, 500